[The optimal duration of adjuvant therapy in breast cancer: what kind of evidence? Hormone therapy: the example of clinical studies].
Giannessi
Pier Giorgio
PG
UO Oncologia Medica, Dipartimento Oncologico, Azienda USL 6, Livorno.
D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D020847:Estrogen Receptor Modulators / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D006801:Humans; D000077289:Letrozole; D015337:Multicenter Studies as Topic; D009570:Nitriles / Q000008:administration & dosage / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D016019:Survival Analysis; D013629:Tamoxifen / Q000008:administration & dosage / Q000627:therapeutic use; D016896:Treatment Outcome; D014230:Triazoles / Q000008:administration & dosage / Q000627:therapeutic use
D018931:Antineoplastic Agents, Hormonal; D004791:Enzyme Inhibitors; D020847:Estrogen Receptor Modulators; D009570:Nitriles; D014230:Triazoles; D013629:Tamoxifen; D000077289:Letrozole